Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28293182 | 0.98 | MAOB (0.55) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| Hydrochloric Acid SCHEMBL29763734 | 0.98 | MAOB (0.55) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| SCHEMBL25720430 | 0.91 | MAOB (0.51) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| SCHEMBL4322263 | 0.85 | MAOB (0.53) | MAOBRAB9AMAPTMAOASMN1; SMN2 | |
| SCHEMBL10903897 | 0.85 | L3MBTL1 (0.55) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| SCHEMBL6461426 | 0.84 | L3MBTL1 (0.48) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| SCHEMBL1143540 | 0.83 | MAOB (0.53) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| SCHEMBL10477402 | 0.83 | APP (0.53) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| SCHEMBL1285187 | 0.82 | MAPT (0.50) | MAOBL3MBTL1RAB9AMAPTMAOA | |
| SCHEMBL1578651 | 0.82 | MAOB (0.59) | MAOBMAOAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573959-B1 | BENZYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3573965-B1 | INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3532458-B1 | BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-01-20 | — | — | EP | disclosed |
| EP-3497085-B1 | SULFONAMIDES AS GPR40- AND GPR120-AGONISTS | DOMPE FARM SPA (IT) | 2020-07-22 | — | — | EP | disclosed |
| EP-3331860-B1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3497085-A1 | SULFONAMIDES AS GPR40- AND GPR120-AGONISTS | Dompé farmaceutici S.p.A. (IT) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169142-A1 | SULFONAMIDES AS GPR40- AND GPR120-AGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-06-06 | — | — | US | disclosed |
| WO-2018138026-A1 | INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018138027-A1 | BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICALCOMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018077699-A1 | BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-03 | — | — | WO | disclosed |
| US-4840772-A | KIT WITH CONTAINERS OF AGENT TO REDUCE INTRAOCULAR PRESSURE AND ANTIINFLAMMATORY STEROID OR BETA-BLOCKER | SCHERING CORPORATION (US) | 1989-06-20 | — | — | US | disclosed |
| US-4783444-A | SUBSTITUTED DIPEPTIDES | SCHERING CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0285219-A2 | Method of improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-05 | — | — | EP | disclosed |
| US-4704401-A | HYPOTENSIVE AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4691049-A | Process for preparing a specific diastereomer of a monoamino dicarboxylic acid ester | SCHERING CORPORATION (US) | 1987-09-01 | — | — | US | disclosed |
| US-4584285-A | Antihypertensive agents | SCHERING CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
| US-4564640-A | Amidinoureas substituted in both the urea and amidino nitrogen positions | WILLIAM H. RORER, INC. (US) | 1986-01-14 | — | — | US | disclosed |
| US-4487779-A | HYPOTENSIVE AGENTS | WILLIAM H. RORER, INC. (US) | 1984-12-11 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-3995041-A | CORONARY VASODILATORS | MILES LABORATORIES, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169142-A1 | SULFONAMIDES AS GPR40- AND GPR120-AGONISTS | GPR119, GPR88, GPR84 | MAOB 4704/4885L3MBTL1 3992/4885RAB9A 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.